Skip to content
MarketScale
‹ Back to IndustriesSciences

Why You Shouldn’t Be Using ‘Conventional’ Methods for Unconventional Drilling

On this episode of the Sciences Podcast, host Tyler Kern dug deep, so to speak, on the topic of using big data for conventional and unconventional reservoirs with two geoscientists from Ikon Science. Today’s guests are Gabi D’Aubeterre], Americas support team manager, and Yoryenys Del Moro, regional product champion for wells. Del Moro said…

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Sciences · DrillingGabi D’aubeterre PodcastGeopredictionGeoscientist
Share

Key takeaways

01

On this episode of the Sciences Podcast, host Tyler Kern dug deep, so to speak, on the topic of using big data for conventional and unconventional reservoirs with two geoscientists from Ikon Science.

02

Today’s guests are Gabi D’Aubeterre], Americas support team manager, and Yoryenys Del Moro, regional product champion for wells.

On this episode of the Sciences Podcast, host Tyler Kern dug deep, so to speak, on the topic of using big data for conventional and unconventional reservoirs with two geoscientists from Ikon Science. Today’s guests are Gabi D’Aubeterre], Americas support team manager, and Yoryenys Del Moro, regional product champion for wells.

Del Moro said current methods are just scratching the surface of what kind of production is possible.

“To get more production, … we need to use more data, including seismic and well information,” she said.

Ikon Science develops pioneering GeoPrediction software technology and solutions to help customers have better hit rates and faster production with reduced cost and cycle time. The quantitative interpretation of seismic and well data has been widely successful for conventional operations around the world but lags in unconventional reservoirs, D’Aubeterre and Del Moro said.

“When it comes to unconventional reservoirs, we need to change our mindset from what we’ve done traditionally,” D’Aubeterre said.

Unconventional reservoirs pose a unique challenge for geoscientists. While the rocks in conventional reservoirs effectively traps oil and gas until it’s drilled, this same trapping mechanism is not present in more difficult unconventional plays. In a conventional reservoir, the type of rock (usually a sandstone) traps the hydrocarbon effectively within its porous space, but this is not the case for unconventional reservoirs.

“In an unconventional reservoir, the hydrocarbons do not flow naturally and are trapped within the rock, within low permeability and low porosity units” D’Aubeterre said. Fracturing the rock and shale to extract that oil and gas makes a challenge for geoscientists and engineers.

Del Moro agreed, saying complications exist when geoscientists and engineers look to fracture the right area of rock for the right natural resource to produce hydrocarbons.

“So you need to apply the techniques that allow you to define and detect what you’re looking for in the shales, fractures, and natural fracture zones,” Del Moro said, explaining seismic data allows you to do that.

D’Aubeterre and Del Moro shared specific examples of quantitative interpretation of seismic and well data in unique settings and how the machine learning and integration.

Read more on the Ikon Science Website.

Follow us on social media for the latest updates in B2B!

Twitter – twitter.com/ScienceMKSL

Facebook – facebook.com/marketscale

LinkedIn – linkedin.com/company/marketscale

About the author

S
Sciences

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one expert. Imagine publishing your whole team.

This article was produced through MarketScale. Create a free workspace and turn your own team's expertise into articles, video, and social posts. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Sciences Insights

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

The pharmaceutical industry is facing a significant challenge as over $300 billion in branded pharmaceutical revenue is set to lose patent protection by 2030. This revenue gap is driving the largest merger and acquisition cycle seen in a decade, with companies seeking external growth through acquisitions. This shift is impacting the entire life sciences supply chain, prompting strategic changes across the industry.

  • 01Over $300 billion in pharmaceutical revenue is at risk due to patent expirations by 2030.
  • 02Big Pharma is engaging in an aggressive cycle of mergers and acquisitions.
  • 03The acquisitions are reshaping the life sciences supply chain.

Jun 29, 2026

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences has initiated a Phase I clinical study at its UK facility for an oral solid dose formulation designed using artificial intelligence — what the company believes is the first AI-formulated drug to reach human clinical evaluation. The study, cleared by the UK's Medicines and Healthcare products Regulatory Agency, will assess safety and pharmacokinetics in healthy volunteers. The program, which used Intrepid Labs' machine learning algorithm, signals a broader shift in how contract drug development organizations are integrating AI across formulation and clinical workflows.

  • 01Quotient Sciences initiated a Phase I study of an AI-designed oral solid dose formulation at its UK facility following MHRA approval — the first such case the company believes has been reported.
  • 02The formulation was developed using Intrepid Labs' advanced machine learning algorithm in combination with Quotient Sciences' Translational Pharmaceutics platform.
  • 03The milestone is part of a broader CRDMO strategy to embed AI-enabled approaches across formulation development and clinical workflows, with implications for the wider contract pharma sector.

Jun 17, 2026

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences has initiated a Phase I clinical study of an oral solid dose formulation designed using AI, cleared by the UK's MHRA and conducted at the company's UK facility. The trial—built on machine learning algorithms from partner Intrepid Labs and Quotient's Translational Pharmaceutics platform—aims to validate AI as a direct contributor to formulation design rather than just an upstream analytical tool. Benchling characterizes the broader moment as biotech entering a "builder phase," in which leading organizations embed AI capability at the bench level rather than running isolated pilots.

  • 01Quotient Sciences has dosed healthy volunteers in a Phase I study it describes as the first clinical evaluation of an AI-designed oral formulation, following approval from the UK's MHRA.
  • 02The formulation was developed using advanced machine learning algorithms from Intrepid Labs, integrated with Quotient Sciences' Translational Pharmaceutics platform.
  • 03Benchling identifies a sector-wide shift toward embedding AI capability directly at the bench, moving beyond isolated pilots to structural adoption across biotech R&D.

Jun 17, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

S
Sciences